Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rufinamide.

Emma D Deeks1, Lesley J Scott

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|September 7, 2006
PubMed
Summary
This summary is machine-generated.

Rufinamide effectively treats seizures in Lennox-Gastaut syndrome and partial seizures by modulating neuronal sodium channels. This anticonvulsant medication demonstrated sustained efficacy and good tolerability in clinical trials for epilepsy management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2022
Same author

Correction to: Abrocitinib: First Approval.

Drugs·2022
Same author

Asciminib: First Approval.

Drugs·2022
Same author

Chiglitazar: First Approval.

Drugs·2021
Same author

Atogepant: First Approval.

Drugs·2021
Same author

Abrocitinib: First Approval.

Drugs·2021
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Neurology

Background:

  • Rufinamide is a triazole derivative with demonstrated anticonvulsant properties.
  • It functions by limiting neuronal sodium channel recovery after inactivation, thereby reducing action potential firing.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of adjunctive oral rufinamide in patients with treatment-resistant Lennox-Gastaut syndrome (LGS).
  • To assess the effectiveness of rufinamide in reducing partial seizure frequency in adult patients with inadequately controlled partial seizures.

Main Methods:

  • A 16-week, placebo-controlled trial in children, adolescents, and adults with LGS.
  • Two separate trials, each approximately 3 months in duration, evaluating rufinamide in adult patients with partial seizures.

Related Experiment Videos

  • A subsequent 3-year open-label extension study to assess long-term efficacy and safety.

    • Main Results:

    • Adjunctive rufinamide significantly reduced the median frequency of total seizures and tonic-atonic seizures in LGS patients compared to placebo.
    • Seizure severity also improved in the rufinamide group.
    • Long-term administration of rufinamide maintained these beneficial effects on seizure frequency.
    • In adult patients, rufinamide significantly decreased partial seizure frequency, with a greater proportion achieving at least a 50% reduction.

    Conclusions:

    • Rufinamide is an effective adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in pediatric and adult populations.
    • Rufinamide demonstrates efficacy in reducing partial seizure frequency in adults.
    • The medication is generally well-tolerated, with most adverse events being mild to moderate.